A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

October 16, 2017


Attendees discuss a poster presentation at IDWeek 2017

IDWeek Roundup

In the world of HIV drug development, several noteworthy candidates are quickly approaching potential U.S. Food and Drug Administration approval. While it's still far too soon to start thinking about regulatory approval of vaccines and more nascent cure research, the results of several large clinical trials on new antiretroviral therapies have been announced, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

These results were presented at a smattering of sessions at IDWeek 2017, Oct. 4-8. Here, we highlight major findings on late-stage antiretroviral candidates, including those discussed in talks by Eric Daar, M.D., Harbor-UCLA Medical Center; Paul Sax, M.D., Brigham and Women's Hospital; and Brinda Emu, M.D., Yale School of Medicine.

Image: Attendees discuss a poster presentation at IDWeek 2017 (Credit: Infectious Diseases Society of America).

Related Stories

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline
Ignorance About PrEP Is Common Among Health Care Providers, Studies Suggest
Long-Acting HIV Treatment: 5 Myths and Realities

This article was provided by It is a part of the publication IDWeek 2017.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.